Cytheris is a privately held clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The company’s lead drug candidate, CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments:

• Progressive Multifocal Leukoencephalopathy (PML) in severely lymphopenic patients; an orphan indication with a one year survival of around 50 per cent that affects approximately 4,000 people year in the US and EU.
• Reduction of complications in Immune Non-Responders with HIV controlled by anti-retroviral treatment (HIV-INR); 15-25 per cent of HIV patients are lymphopenic despite optimal treatment (HAART) leading to a significant increase in risk of death and serious complications.

CYT107 is a critical growth factor for immune T cell recovery and enhancement. Clinical trials conducted on more than 240 patients have demonstrated the ability of CYT107 to expand and protect CD4+ and CD8+ T-cells in various pathologic conditions as well as a consistent safety and tolerability profile. Cytheris is based in Issy-les-Moulineaux, close to Paris and currently has 33 employees.